samedan logo
 
 
 
spacer
home > ebr > summer 2004 > performance comparison of 60-mer and 25-mer in situ synthesised oligonucleotide microarrays
PUBLICATIONS
European Biopharmaceutical Review

Performance Comparison of 60-mer and 25-mer In Situ Synthesised Oligonucleotide Microarrays

Studies have suggested that 60-mer probes are more sensitive than 25-mer probes in microarray experiments, due to the longer length available for hybridisation (1). 60-mers are also more tolerant of sequence mismatches, which results in simplified analysis of highly polymorphic regions through the use of longer probes. We followed two different experimental approaches to compare the performance of 25-mers and 60-mers.

In the initial experiments, we evaluated two different microarrays manufactured with in situ synthesis inkjet printing, one employing 25-mer probes and the other 60-mer probes for each yeast open reading frame. In the second series of experiments, we evaluated 25-mer and 60-mer probes representing 500 human genes on a custom array containing 22,525 features. The genes were selected for this microarray either because they were known to be cancer related or because they were observed as up or down regulated in colon cancer samples experiments performed with Agilent Human 1A microarrays in earlier studies.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Stephanie Fulmer-Smentek, Senior R&D Research Scientist at Agilent Technologies Inc and Luis Lombardia, Research Associate at Centro Nacional de Investigaciones Oncologicas (CNIO)*

Stephanie Fulmer-Smentek earned her PhD in Human Genetics from Johns Hopkins University in 1997. She then undertook postdoctoral research at Stanford University in the Department of Genetics. Stephanie joined Agilent Technologies Inc in 2000, and is now a Senior R&D Research Scientist in the Bioresearch Solutions Unit.


Luis Lombardia earned his PhD from Universidade Da Coruсa in 1998. He then spent two years as a postdoctoral fellow in CEA (Commisariat а l'Йnergie Atomique, Paris, France). Since 2001, Luis has been a Research Associate in the Genomics Unit of the Centro Nacional de Investigaciones Oncolуgicas.

spacer
Stephanie Fulmer-Smentek
spacer
spacer
spacer
Luis Lombardia
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases

MyMD Pharmaceuticals Inc., a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,085,047 titled “Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders.”
More info >>

White Papers

What Your Clinical Study Design Reveals About Your Clinical Packaging Needs

PCI Pharma Services

As the cost and complexities of drug development increase, so do the challenges of global clinical trials. Today’s sponsors must be able to manage and coordinate multiple resources, processes, and locations with speed and accuracy to design effective and efficient clinical trials. Securing a stable supply chain to deal with the uncertainties of clinical trials is critical. One misstep can have a profound impact not only on the cost and time of your trial but also on its overall success.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement